Cancer vaccines: Building a bridge over troubled waters

MLC Sellars, CJ Wu, EF Fritsch - Cell, 2022 - cell.com
Cancer vaccines aim to direct the immune system to eradicate cancer cells. Here we review
the essential immunologic concepts underpinning natural immunity and highlight the …

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial

RD Carvajal, MO Butler, AN Shoushtari, JC Hassel… - Nature medicine, 2022 - nature.com
In patients with previously treated metastatic uveal melanoma, the historical 1 year overall
survival rate is 37% with a median overall survival of 7.8 months. We conducted a …

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

ZJF Assaf, W Zou, AD Fine, MA Socinski, A Young… - Nature Medicine, 2023 - nature.com
One of the great challenges in therapeutic oncology is determining who might achieve
survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA …

Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models

R Bruno, P Chanu, M Kågedal, F Mercier… - British journal of …, 2023 - nature.com
Longitudinal models of biomarkers such as tumour size dynamics capture treatment efficacy
and predict treatment outcome (overall survival) of a variety of anticancer therapies …

Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small …

Z Eslami-S, LE Cortés-Hernández, L Sinoquet… - British Journal of …, 2024 - nature.com
Abstract Background Circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), and
extracellular vesicles (EVs) are minimally invasive liquid biopsy biomarkers. This study …

Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer

SH Tolmeijer, E Boerrigter, T Sumiyoshi, EM Kwan… - Clinical Cancer …, 2023 - AACR
Purpose: Androgen receptor pathway inhibitors (ARPI) are standard of care for treatment-
naïve metastatic castration-resistant prostate cancer (mCRPC), but rapid resistance is …

Explainable deep learning for tumor dynamic modeling and overall survival prediction using Neural-ODE

M Laurie, J Lu - npj Systems Biology and Applications, 2023 - nature.com
While tumor dynamic modeling has been widely applied to support the development of
oncology drugs, there remains a need to increase predictivity, enable personalized therapy …

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

R Thummalapalli, B Ricciuti, C Bandlamudi… - Clinical Cancer …, 2023 - AACR
Purpose: We sought to identify features of patients with advanced non–small cell lung
cancer (NSCLC) who achieve long-term response (LTR) to immune checkpoint inhibitors …

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)

PC Mack, J Miao, MW Redman, J Moon… - Clinical Cancer …, 2022 - AACR
Purpose: Dynamic changes in circulating tumor DNA (ctDNA) are under investigation as an
early indicator of treatment outcome. Experimental Design: Serial plasma ctDNA (baseline, 8 …

Liquid biopsy in lung cancer: biomarkers for the management of recurrence and metastasis

VGP Souza, A Forder, LJ Brockley… - International Journal of …, 2023 - mdpi.com
Liquid biopsies have emerged as a promising tool for the detection of metastases as well as
local and regional recurrence in lung cancer. Liquid biopsy tests involve analyzing a …